Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Sherman

Showing results (31-40 of 113) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic CarcinomaVatche Tchekmedyian, Eric J Sherman, Lara Dunn, et al.
Cancers of the Head & Neck|May 17, 2019
Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancerShrujal S Baxi, Talya Salz, Han Xiao, et al.
Cancer Discovery|February 1, 2013
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomasCristina Montero-Conde, Sergio Ruiz-Llorente, Jose M Dominguez, et al.
Endocrine|February 4, 2017
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I Haddad, Martin Schlumberger, Lori J Wirth, et al.
Cancer|March 3, 2015
Treatment-related toxicities in older adults with head and neck cancer: A population-based analysisCaitriona B O'Neill, Shrujal S Baxi, Coral L Atoria, et al.
Journal of Surgical Oncology|June 26, 2014
External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancerPaul B Romesser, Eric J Sherman, Ashok R Shaha, et al.
The Lancet. Oncology|February 5, 2026
Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort studyCaineng Cao, Eric J Sherman, Nadeem Riaz, et al.
Oral Oncology|May 12, 2015
Definitive chemoradiation for primary oral cavity carcinoma: A single institution experienceEli D Scher, Paul B Romesser, Christine Chen, et al.
Cancer|June 8, 2019
Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancerEric J Sherman, Lara A Dunn, Heiko Schöder, et al.
Oral Oncology|August 19, 2014
Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC)Lauren Q Shapiro, Eric J Sherman, Nadeem Riaz, et al.
Pageof 12

Showing results (31-40 of 113) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic CarcinomaVatche Tchekmedyian, Eric J Sherman, Lara Dunn, et al.
Cancers of the Head & Neck|May 17, 2019
Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancerShrujal S Baxi, Talya Salz, Han Xiao, et al.
Cancer Discovery|February 1, 2013
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomasCristina Montero-Conde, Sergio Ruiz-Llorente, Jose M Dominguez, et al.
Endocrine|February 4, 2017
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I Haddad, Martin Schlumberger, Lori J Wirth, et al.
Cancer|March 3, 2015
Treatment-related toxicities in older adults with head and neck cancer: A population-based analysisCaitriona B O'Neill, Shrujal S Baxi, Coral L Atoria, et al.
Journal of Surgical Oncology|June 26, 2014
External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancerPaul B Romesser, Eric J Sherman, Ashok R Shaha, et al.
The Lancet. Oncology|February 5, 2026
Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort studyCaineng Cao, Eric J Sherman, Nadeem Riaz, et al.
Oral Oncology|May 12, 2015
Definitive chemoradiation for primary oral cavity carcinoma: A single institution experienceEli D Scher, Paul B Romesser, Christine Chen, et al.
Cancer|June 8, 2019
Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancerEric J Sherman, Lara A Dunn, Heiko Schöder, et al.
Oral Oncology|August 19, 2014
Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC)Lauren Q Shapiro, Eric J Sherman, Nadeem Riaz, et al.
Pageof 12